CardioVascular Disease Progression and Prognosis in COVID-19

Cardiovascular Clinical Features and Cardiovascular Therapies in the Development, Progression and Outcome of Patients with SARS-Cov-2 Related Pneumonia

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04606732

Acronym

CVP-Covid19

Enrollment

2000

Registered

2020-10-28

Start date

2020-09-20

Completion date

2025-12-31

Last updated

2025-03-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Covid19

Keywords

Cardiovascular Diseases, Pneumonia, Viral, SARS-CoV-2, Covid-12, ACE receptor

Brief summary

The CVP-COVID19 registry is both a retrospective and prospective study design in order to identify predictors of cardiovascular disease progression and mortality for COVID-19. The registry enrolls consecutive patients with positive microbiological tests for SARS-CoV-2 admitted to an academic hospital in northern Italy for worsening of COVID-19 symptoms. The study does not test any new diagnostic or therapeutic approach. Patients are treated according to good clinical practice. Patients characteristics, including medical history (with particular attention to cardiovascular and pneumological risk factors), features of physical examination, results laboratory and radiological tests and treatments (pre- and in-hospital) are related with patient outcome. Logistic analysis (univariate, multivariate and propensity) are performed in order to identify factors associated with disease progression. Primary endpoint: mortality.

Detailed description

Members of the Steering Committee: Olivia Manfrini (Università di Bologna, Italy) Raffaele Bugiardini (Università di Bologna, Italy) Stefano Nava (Università di Bologna, Italy) Elisabetta Poluzzi (Università di Bologna, Italy) Maria Carla Re (Università di Bologna, Italy) Caterina Vocale (Policlinico Sant'Orsola) Study Coordinator: Edina Cenko (Università di Bologna, Italy)

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

CROSS_SECTIONAL

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

hospitalization for COVID-19

Exclusion criteria

age \<18 years

Design outcomes

Primary

Measure	Time frame	Description
Mortality	30 days	All causes mortality

Countries

Italy

Contacts

Primary ContactOlivia Manfrini, MD

olivia.manfrini@unibo.it+393355612175

Outcome results